STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Bisnortilidine

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled ✓
- Not Controlled □

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance is a metabolite of tilidine and therefore included under item 17 of Schedule I to the CDSA.

Prepared by: ____________________________ Date: Nov 26th 2010

Evelyn Soo

Verified by: ____________________________ Date: __________

Marianne Tang

Approved by: ____________________________ Date: __________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: "third party information removed as per agreement with applicant"
Drug Status Report

**Drug**: Bisnortilidine

**Drug Name Status**: Bisnortilidine is the common name.

**Chemical Name**: Trans-(±)-2-amino-1-phenyl-3-cyclohexene-1-carboxylic acid, ethyl ester

**Chemical structure**:

![Chemical structure diagram]

**Molecular Formula**: \( C_{15}H_{19}NO_2 \)

**Pharmacological class /Application**: Metabolite of tilidine

**CAS-RN**: 53948-51-9

**International status**:

US: Bisnortilidine is not currently listed in the schedules to US Controlled Substances Act nor mentioned anywhere on the DEA webwsite.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: Bisnortilidine is not listed specifically in the CDSA. However, the substance is a metabolite of tildine\(^1\) and therefore is captured under the heading “Tilidine (ethyl-2-(dimethylamino)-1-phenyl-3-cyclohexene-1-carboxylate), its salts, derivatives and salts of derivatives” of item 17 of Schedule I to the CDSA as a derivative of tilidine.

**Recommendation**: Bisnortilidine is included under item 17 of Schedule I to the CDSA and is a controlled substance.

**Date**: 26 November 2010

---